1. No category

Organizing Committee
Dr. Amina Zoubeidi
Dr. Koroush Afshar
Dr. Peter Black
Dr. Ben Chew
9th Annual
Lorne D. Sullivan Lectureship
and Research Day
Learning Objectives
To inform members of the types of clinical and
basic science research being conducted in the
department of Urologic Sciences
To familiarize members with new innovative
research techniques
To foster an atmosphere of collaborative
research within the department of Urologic
Sciences
Contact Us
Department of Urologic Sciences
2775 Laurel Street, 6th Floor
Gordon & Leslie Diamond Health Care Centre
Vancouver, BC, V5Z 1M9
Phone: 604-875-4301
Fax: 604-875-4637
email: [email protected]
Tuesday, June 16, 2015
Paetzold Health Education Centre Auditorium
Jim Pattison Pavilion, VGH, Vancouver, BC
Program
2015 Sullivan Research Lecturer
John M. Barry, MD
Professor of Urology
Professor of Surgery and Abdominal Organ Transplantation, School of
Medicine, Oregon Health & Science University, USA
Gold Sponsors:
Silver Sponsors:
Dr. Barry is a product of the public
education systems of Minnesota and
Oregon. He has spent his entire academic
career at the Oregon Health & Science
University (OHSU) in Portland where he is
currently Professor of Surgery in the
Division
of
Abdominal
Organ
Transplantation and Professor of Urology.
He was Director of the Kidney Transplant
Program from 1976 to 2009, Chief of the
Division
of
Abdominal
Organ
Transplantation from 2000-2002, and
Chief of the Division of Urology from 1979
to 2008.
He has been President of the following organizations: Pine City High
School Senior Class, University of Minnesota Freshman Medical
School Class, Western Section of the American Urological Association
(AUA), Northwest Urological Society, Oregon Urological Society,
Western Association of Transplant Surgeons, Pacific Northwest
Transplant Society, Urologic Society for Transplantation and Renal
Surgery (twice), the AUA, and the American Board of Urology. He has
had >300 publications and two wives (in sequence), and done >2,400
kidney transplants. Probably the only thing he’ll be remembered for
is the development of the stamp test for nocturnal penile tumescence
testing. He continues to practice as a transplant surgeon and general
urologist at OHSU.
The Paetzold Auditorium is on the first floor of Jim Pattison Pavilion
South, just north of the information booth.
1
6
6
6
12:04 PM-12:11 PM
Struvite stones, bacteria and antibiotics. A multiinstitutional experience, as basis for larger
international prospective randomized trial
Ryan Flannigan et al
Lunch & Posters:
Welcome:
08:00 AM-08:15 AM
12:11 PM-1:00 PM
Dr. Howard Feldman
Professor of Neurology, Executive Associate
Dean, Research, Faculty of Medicine, UBC
State of Art, Lecture 2:
1:00 PM-1:20 PM
Future of immunotherapy in urological
malignancy
Dr. Robert McMaster
VP Research, Vancouver Coastal Health,
Executive Director, VCHRI, Associate Dean
Research, Faculty of Medicine, UBC
Dr. Jennifer Bishop
Session 4: Novel diagnostic and therapeutics
(7min talk and 3min Q&A)
1:20 PM-2:20 PM
Moderator: Dr. Amina Zoubeidi
1:20 PM-1:30PM
Characterization of circulating DNA
mutations to monitor anti-androgen
resistance in CRPC patients
Nada Lallous (Rennie, Collins & Cherkasov’s
labs)
1:30 PM-1:40 PM
Selectivity targeting the DNA-binding domain
of the androgen receptor as a prospective
therapy for prostate cancer
Kush Dalal (Rennie’s lab)
1:40 PM-1:50 PM
Catalytic inhibitors of DNA topoisomerase
II suppress the androgen receptor signaling
and prostate cancer progression
Haolong Li (Dong’s lab)
1:50 PM-2:00 PM
The lactate transporter MCT4 as a potential
therapeutic target in urothelial carcinoma
Tilman Todenhöfer (Black’s lab)
2:00 PM-2:10 PM
2:10 PM-2:20 PM
Lorne D. Sullivan Lectureship
08:15 AM-08:45 AM
Targeting chondroitin sulfate chains on
TMEFF2 in prostate cancer
Nader Al Nakouzi (Daugaard’s lab)
Dr. John Barry, MD
Professor of Urology and Abdominal Organ
Transplantation, School of Medicine, Oregon
Health & Science University, USA
“The Urinary Tract Before, During, and After
Renal Transplantation”
Session 1: Clinical
(5min talk and 2min Q&A)
08:45 AM-09:41 AM Moderator: Dr. Alan So
08:45 AM-08:52AM
Testosterone replacement therapy among
patients with prostate cancer managed by
surgery, radiation, and active surveillance.
Jesse Ory et al
08:52 AM-08:59 AM
Natural history of prostatic lesions on serial
multi-parametric MRI
Samrad Ghavimi et al
08:59 AM-09:06 AM
Chondroitin sulfate is a novel therapeutic
target in bladder cancer
Htoo Zarni Oo (Daugaard’s lab)
Dr. Martin Gleave
Head of the Department of Urologic Sciences &
Director of the Vancouver Prostate Centre, UBC
Ulrasound-based detection of prostate cancer
using automatic feature selection with deep
belief network: A clinical feasibility study
Shekoofeh Azizi et al
09:06 AM-09:13 AM
Neutrophil-to-lymphocyte ratio predicts adverse
outcome in patients with high grade T1 bladder
cancer undergoing radical cystectomy
Hamid Abdi et al
Adjourn
5
2
6
6
09:13 AM-09:20 AM
09:20 AM-09:27 AM
Implementation of the prostate cancer
supportive care (PCSC) program, A
comprehensive approach for men with prostate
cancer and their partners
CS Higano et al
Impact of first-line cisplatin versus non-cisplatin
based chemotherapy on progression-free
survival in patients with advanced urothelial
carcinoma previously treated with perioperative
cisplatin based chemotherapy
10:45 AM–10:55 AM
Mani R. Moniri (Cherkasov and Rennie’s lab)
10:55 AM-11:05 AM
9:34 AM-09:41 AM
11:05 AM-11:15 AM
Varune Rohan Ramnarine (Collin’s lab)
Session 3: Clinical
Richard Savdie et al
(5min talk and 2min Q&A)
11:15 AM-12:11 PM Moderator: Dr. Chris Nguan
Long term outcomes of active surveillance for
favourable risk prostate cancer
11:15 AM-11:22AM
State of Art, Lecture 1:
09:41 AM-10:01 AM
From personalized genomics to precision oncology
Break:
10:01 AM-10:15 AM
Dr. Alex Wyatt
(7min talk and 3min Q&A)
11:22 AM-11:29 AM
11:29 AM-11:36 AM
11:36 AM-11:43 AM
Targeting the treatment-induced developmental
reprogramming process that facilitates
progression of prostate cancer
Ultra-structural defects in immotile sperm:
Characterization of electron microscopy findings
Ryan Flannigan et al
11:43 AM-11:50 AM
Natural history, complications, and re-intervention
rates of asymptomatic residual stone fragments
post-ureteroscopy: A report from the EDGE
research consortium
Hilary Brotherhood et al
11:50 AM-11:57 AM
Robotic assisted laparoscopic radical
prostatectomy: A seven-year experience
Hamid Abdi et al
Josselin Caradec (Buttyan’s lab)
10:35 AM-10:45AM
Upright MRI in the evaluation of genuine stress
urinary incontinence: A comparison of pre and
post-operative findings in patients undergoing
MonarcR trans-obterator sling surgery
Treissman SP et al
Alastair H Davies (Zoubeidi’s lab)
Gene signature of developmentally-reprogrammed prostate cancer cells identifies
patients with adverse outcomes
Optical diagnosis of acute scrotum in children
Babak Shadgan et al
10:15 AM-11:15 AM Moderator: Dr. Michael Cox
Phenotypic switching: Tumor cell plasticity as a
mechanism of prostate cancer cell plasticity and
target for therapy
Patients with HelicalTM ureteral stents require
significantly less analgesics than control stents
David Harriman et al
Session 2: Cell plasticity & treatment resistance
10:25 AM-10:35 AM
Prognostic long non-coding RNAs involved in
prostate cancer progression and treatment
resistance
Evaluation of MRI-Ultrasound fusion biopsy
versus systematic transrectal ultrasound guided
prostate biopsy employing new PIRADS scoring
Richard Savdie et al
10:15 AM-10:25AM
Inhibition of Bromodomain as a therapeutic
target in prostate cancer—Results from preclinical modeling
Samir Bidnur (Zoubeidi’s lab)
Jennifer Locke et al
09:27 AM-09:34 AM
Therapeutic targeting of ETS factors for
treatment of prostate cancer
11:57 AM-12:04 PM
Development and validation of the Canadian men’s
health risk assessment tool: “YOU CHECK”
Farshad Pourmalek et al
Mannan Nouri (Buttyan’s lab)
4
3
6
6